Adap­ti­m­mune an­nounced Wednes­day that its ex­per­i­men­tal cell ther­a­py based on T cell re­cep­tors shrank tu­mors by ...

Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...

John­son & John­son is su­ing the fed­er­al gov­ern­ment over its re­buke of the com­pa­ny’s al­ter­na­tive mod­el for 340B ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

Flag­ship Pi­o­neer­ing has ap­point­ed two new CEO-part­ners to ad­vise its port­fo­lio com­pa­nies and help steer its ...

A lot of Am­gen’s fu­ture rides on its ex­per­i­men­tal obe­si­ty med­i­cine Mar­i­Tide. At least in the minds of in­vestors.

Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...